Form 4: Boston Scientific EVP Gifts Shares Under 10b5-1 Plan

Boston Scientific's EVP & Group President of Cardiology, Joseph Michael Fitzgerald, reported gifting 10,300 shares of common stock in November 2025.

Summary

• Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific Corp (BSX), reported changes in beneficial ownership.
• On November 12, 2025, Fitzgerald disposed of 690 shares of common stock via gift (Transaction Code G) at a price of $0.0000.
• On November 14, 2025, Fitzgerald disposed of an additional 9,610 shares of common stock via gift (Transaction Code G) at a price of $0.0000.
• Following these transactions, Fitzgerald directly beneficially owns 168,042 shares of common stock.
• An additional 5,234 shares are indirectly owned by his child, for which Fitzgerald disclaims beneficial ownership.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The filing reports an executive gifting shares, which is a reduction in direct beneficial ownership but not a sale for cash. The transactions were pre-planned under a Rule 10b5-1 plan, indicating no immediate market-timing intent.

Positives

• The transactions were gifts, not sales, indicating no direct cash out by the executive.
• The transactions were made under a Rule 10b5-1(c) plan, suggesting pre-planned and not reactive selling.

Negatives

• A reduction in direct beneficial ownership by a key executive, even through gifts, slightly decreases insider alignment.

Related Party Transactions

• The indirect ownership of 5,234 shares by the reporting person's child, although beneficial ownership is disclaimed, represents a related party holding.

Stakeholder Impact

• Shareholders: A slight reduction in direct insider ownership, potentially viewed as a minor decrease in alignment, though mitigated by the gift nature and 10b5-1 plan.

Key Dates

Recommendation

The filing details an executive's gift of shares, which is a routine insider transaction and not indicative of a change in the company's fundamental performance or outlook. While it reduces direct insider ownership, it's not a sale for cash and was executed under a pre-arranged plan. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Boston Scientific, BSX, Form 4, Insider Transaction, Joseph Michael Fitzgerald, Stock Gift, Executive Ownership, Rule 10b5-1